

RESEARCH ARTICLE


Impact of smoking on stroke outcome after endovascular treatment

Rascha von Martial¹, Jan Gralla², Pasquale Mordasini², Marwan El Koussy², Sebastian Bellwald¹, Bastian Volbers¹, Rebekka Kurmann¹, Simon Jung¹, Urs Fischer¹, Marcel Arnold¹, Hakan Sarikaya^{1*}

1 Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland,

2 Department of Diagnostic and Interventional Neuroradiology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland

* hakan.sarikaya@insel.ch



Abstract

Background

Recent studies suggest a paradoxical association between smoking status and clinical outcome after intravenous thrombolysis (IVT). Little is known about relationship between smoking and stroke outcome after endovascular treatment (EVT).

Methods

We analyzed data of all stroke patients treated with EVT at the tertiary stroke centre of Berne between January 2005 and December 2015. Using uni- and multivariate modeling, we assessed whether smoking was independently associated with excellent clinical outcome (modified Rankin Scale (mRS) 0–1) and mortality at 3 months. In addition, we also measured the occurrence of symptomatic intracranial hemorrhage (sICH) and recanalization.

Results

Of 935 patients, 204 (21.8%) were smokers. They were younger (60.5 vs. 70.1 years of age, $p < 0.001$), more often male (60.8% vs. 52.5%, $p = 0.036$), had less often from hypertension (56.4% vs. 69.6%, $p < 0.001$) and were less often treated with antithrombotics (35.3% vs. 47.7%, $p = 0.004$) as compared to nonsmokers. In univariate analyses, smokers had higher rates of excellent clinical outcome (39.1% vs. 23.1%, $p < 0.001$) and arterial recanalization (85.6% vs. 79.4%, $p = 0.048$), whereas mortality was lower (15.6% vs. 25%, $p = 0.006$) and frequency of sICH similar (4.4% vs. 4.1%, $p = 0.86$). After correcting for confounders, smoking still independently predicted excellent clinical outcome (OR 1.758, 95% CI 1.206–2.562; $p < 0.001$).

Conclusion

Smoking in stroke patients may be a predictor of excellent clinical outcome after EVT. However, these data must not be misinterpreted as beneficial effect of smoking due to the

OPEN ACCESS

Citation: von Martial R, Gralla J, Mordasini P, El Koussy M, Bellwald S, Volbers B, et al. (2018) Impact of smoking on stroke outcome after endovascular treatment. PLoS ONE 13(5): e0194652. <https://doi.org/10.1371/journal.pone.0194652>

Editor: Yoshiaki Taniyama, Osaka University Graduate School of Medicine, JAPAN

Received: May 11, 2017

Accepted: March 7, 2018

Published: May 2, 2018

Copyright: © 2018 von Martial et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: HS has received research grants from Bangerter Foundation, Hermann Klaus Foundation, the Swiss Heart Foundation and the Swiss National Science Foundation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: HS has received funding for speaker honoraria from Biogen and Mepha, he has

served on scientific advisory boards for Bayer, Boehringer-Ingelheim, BMS/Pfizer, Biogen, Merck and Novartis. The other authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

observational study design. In view of deleterious effects of cigarette smoking on cardiovascular health, cessation of smoking should still be strongly recommended for stroke prevention.

Introduction

Smoking is an independent risk factor for ischemic stroke especially in younger people.[1] The World Health Organization (WHO) estimates that smoking causes about six million deaths worldwide per year, with increasing incidences especially in developing countries.[2] Though detrimental effects on vascular health, recent studies report better clinical outcome in smokers treated with thrombolysis, which is termed as “smoking paradox”. It was first described in patients with myocardial infarction undergoing intravenous thrombolysis (IVT).[3, 4] Similar associations have also been reported for smoking, favorable 3-month outcome and recanalization in stroke patients treated with IVT.[5] Little is known about relationship between smoking status and stroke outcome after endovascular treatment (EVT), which is increasingly preferred for treatment of severe strokes with large artery occlusion.[6–9]

Methods

This study was based on the Bernese stroke center database, a systematic prospective registry of consecutive patients with ischemic stroke treated at the Stroke Center of University Hospital of Berne, Switzerland. It was approved by the Local Ethics Committee Bern. For this study, we analyzed all stroke patients who underwent EVT (mechanical thrombectomy and/or intraarterial thrombolysis (IAT) with urokinase) between January 2005 and December 2015. The following variables and stroke risk factors were prospectively collected as defined previously:[10–12] age, sex, smoking status, antithrombotic medication at stroke onset, diabetes mellitus, hypertension, hypercholesterolemia, functional independence before stroke (according to modified Rankin Scale (mRS)), stroke etiology according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria, stroke onset-to-treatment time as well as blood pressure and blood glucose level obtained on admission. Patients were classified as smokers when they reported active cigarette use. Severity of the neurological deficit was assessed by a stroke neurologist at admission by using the National Institutes of Health Stroke Scale (NIHSS) score.[13] All patients underwent immediate brain imaging by magnetic resonance imaging (MRI) or computer tomography (CT). We performed EVT according to international and institutional guidelines as described previously. Patients were treated with intra-arterial urokinase, mechanical interventions, or both. Patients within time window of 3 to 4.5 hours were additionally treated with IVT.[14–16] Vessel occlusion and collateral supply was monitored with conventional angiography by an interventional neuroradiologist.[17, 18] Localization of arterial occlusion was categorized depending on size as large vessel (internal carotid artery including carotid-T) vs. medium vessel occlusion (e.g. M1-segment of middle cerebral artery and basilar artery). Collaterals were classified as poor, if none or minimal leptomeningeal anastomoses were visualized and no or minimal filling of the occluded vessel territory was seen, and good, if leptomeningeal anastomoses filled the occluded vessel territory by more than half.[17, 18] All patients treated with EVT were admitted to intermediate or intensive care unit or stroke unit for at least 24 hours. All patients underwent brain imaging with MRI or CT 24 hours after intervention and in any case of clinical deterioration. Symptomatic intracranial hemorrhage (sICH) was defined according to ECASS II criteria.[19] Status of recanalization

was assessed immediately after EVT by using the Thrombolysis in Myocardial infarction (TIMI) score on angiography.[20, 21] Partial or complete recanalization (TIMI scores 2 and 3) were classified as successful recanalization.[22–24] Primary endpoints were excellent clinical outcome at 3 months after stroke (mRS 0 or 1), death within 3 months (mRS 6) and the occurrence of sICH. Secondary endpoint was the frequency of successful recanalization after EVT. The endpoints were prospectively assessed during hospital stay and/or 3-month outpatient visits.

Statistical analyses

We compared demographic and baseline characteristics between smokers and nonsmokers by using Pearson's chi-squared test for categorical variables and two-tailed t-test for continuous variables (or Mann-Whitney U test for skewed distribution). The independent effect of smoking status on endpoints was assessed in multivariate analyses using blockwise regression model. Multivariable adjustment was applied for significant baseline differences between smokers and nonsmokers. Level of significance was set to $p < 0.05$. Furthermore, we performed subgroup analyses for patients treated with mechanical thrombectomy only and for those undergoing intra-arterial thrombolysis (IAT) with urokinase (\pm mechanical thrombectomy), respectively. The level of statistical significance was set to 0.05. Statistical analysis was made using the SPSS Version 21.0.

Results

Baseline characteristics

A total of 935 patients were eligible for this study. Of these, 204 (21.8%) were current smokers. Thrombolysis with IAT was performed in 405 (43.3%) patients, while 285 (30.5%) underwent mechanical thrombectomy only and 245 (26.2%) were treated with intra-arterial urokinase in combination with intravenous alteplase. The main baseline characteristics of the 2 groups are detailed in Table 1. Compared with nonsmokers, smokers were younger and more often male. They suffered less often from arterial hypertension, more often from hypercholesterolemia and were less often treated with antithrombotics. On admission, NIHSS and systolic blood pressure were significantly lower in smokers. Large-artery atherosclerosis was more often the underlying stroke reason in smokers, whereas cardioembolism was the leading stroke cause in nonsmokers. Baseline imaging revealed more often an occlusion of large arteries in smokers than in the counterpart. In analogy, pure mechanical thrombectomy was more often performed in smokers, whereas nonsmokers underwent more often IAT.

Outcomes

Outcomes are summarized in Fig 1. At 3 months, smokers showed significantly higher rates of excellent clinical outcome and lower mortality rates as compared to nonsmokers (39.1% vs. 23.1%, $p < 0.001$ and 15.6% vs. 25%, $p = 0.006$, respectively), whereas the risk of sICH was comparable in both groups (4.4% vs. 4.1%, $p = 0.006$). The frequency of successful recanalization was higher in smokers than in nonsmokers (85.6% vs. 79.4%, $p = 0.048$). In line with this, stroke severity measured by NIHSS at 24 hours after treatment was significantly lower in smokers as compared to the counterpart (7.0 vs. 10.0, $p = 0.005$).

Details of multivariate analyses are shown in S1 Table. Adjustment was made for following variables with statistically significant differences at baseline: age, sex, NIHSS and systolic blood pressure at admission, smoking status and antithrombotics before stroke onset, stroke etiology according to TOAST criteria, localization of occluded vessel and hypercholesterolemia.

Table 1. Baseline characteristics in smoking and nonsmoking stroke patients.

	All Patients (n = 935)	Smokers (n = 204)	Nonsmokers (n = 731)	p
Mean age ± SD, years	68 ± 13.9	60.5 ± 12.1	70.1 ± 13.7	<0.001
Male gender	508/935 (54.3)	124/204 (60.8)	384/731 (52.5)	0.036
Diabetes mellitus	152/935 (16.3)	26/204 (12.7)	126/731 (17.2)	0.124
Arterial hypertension	624/935 (66.7)	115/204 (56.4)	509/731 (69.6)	<0.001
Hypercholesterolemia	527/925 (57)	128/203 (63.1)	399/722 (55.3)	0.048
Antithrombotic pretreatment	342/761 (44.9)	60/170 (35.3)	282/591 (47.7)	0.004
Functional independency before stroke (mRS 0–2)	890/934 (95.3)	198/204 (97.1)	692/730 (94.8)	0.177
NIHSS at admission, median (IQR)	15.0 (10–19)	14.0 (9–18)	15.0 (10–20)	0.024
Mean systolic blood pressure/mmHg ± SD	154 ± 27.5	149 ± 26.8	156 ± 27.5	0.006
Mean glucose/mmol/l ± SD	7.18 ± 2.29	6.87 ± 2.16	7.26 ± 2.36	0.062
Median time to treatment/min (IQR)	274 (213–355)	280 (224–359)	273 (210–351)	0.436
Stroke etiology (TOAST)				<0.001
- large artery atherosclerosis	139/932 (14.9)	49/203 (24.1)	90/729 (12.3)	
- cardioembolic	409/932 (43.9)	60/203 (29.6)	349/729 (47.9)	
- others, n (%)	45/932 (4.8)	10/203 (4.9)	35/729 (4.8)	
- undetermined, n (%)	339/932 (36.4)	84/203 (41.4)	255/729 (35)	
Localization of arterial occlusion				0.01
- large vessel, n (%)	200/817 (24.5)	54/168 (32.1)	146/649 (22.5)	
- medium vessel, n (%)	617/817 (75.5)	114/168 (67.9)	503/649 (77.5)	
Good collaterals, n (%)	302/792 (38.1)	62/158 (39.2)	240/634 (37.9)	0.828
Type of treatment				0.031
- IAT	405/935 (43.3)	73/204 (35.8)	332/731 (45.4)	
- IAT + IVT	245/935 (26.2)	56/204 (27.5)	189/731 (25.9)	
- mechanical thrombectomy	285/935 (30.5)	75/204 (36.8)	210/731 (28.7)	

Results are expressed in n/N (%) unless otherwise denoted

IA denotes intra-arterial thrombolysis with urokinase, IQR interquartile range, IV intravenous thrombolysis with alteplase, min minute, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, SD standard deviation, TOAST Trial of Org 10172 in Acute Stroke Treatment.

<https://doi.org/10.1371/journal.pone.0194652.t001>




Fig 1. Outcomes in smoking vs. non-smoking stroke patients after endovascular treatment. Results are expressed in n/N (%). CI confidence interval, mRS modified Rankin Scale, OR odds ratio, sICH symptomatic intracranial hemorrhage. ¹ adjusted for age, sex, NIHSS on admission, systolic blood pressure on admission, stroke etiology, localization of occluded vessel, hypercholesterolemia and use of antithrombotic pretreatment.

<https://doi.org/10.1371/journal.pone.0194652.g001>

Table 2. Outcomes after mechanical thrombectomy only in smoking vs. nonsmoking patients.

	All patients (n = 285)	Smokers (n = 75)	Nonsmokers (n = 210)	p
Excellent clinical outcome (mRS 0–1)	63/265 (23.8)	26/70 (37.1)	37/195 (19)	0.002
Death	68/265 (25.7)	14/70 (20)	54/195 (27.7)	0.206
sICH	13/284 (4.6)	6/75 (8)	7/209 (3.3)	0.098
Successful recanalization	235/277 (84.8)	64/74 (86.5)	171/203 (84.2)	0.644

Results are expressed in n/N (%)

mRS denotes modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale and sICH, symptomatic intracranial hemorrhage

<https://doi.org/10.1371/journal.pone.0194652.t002>

Multivariate analyses revealed current smoking status as an independent predictor of excellent clinical outcome (Odds ratio (OR) 1.758, 95% confidence interval (95% CI) 1.206–2.562, $p < 0.001$) together with age and baseline NIHSS score. Mortality at 3 months was also independently associated with age and baseline NIHSS, but not with smoking status (OR 0.868, 95% CI 0.531–1.420, $p = 0.573$). None of the variables was independently associated with sICH, this was also true for smoking status (OR 1.027, 95% CI 0.478–2.206, $p = 0.945$). Hypercholesterolemia and large vessel occlusion were identified as independent predictors of recanalization after EVT, whereas no association was observed with smoking status (OR 1.344, 95% CI 0.832–2.173, $p = 0.227$).

We additionally performed subgroup analyses with focus on patients undergoing mechanical thrombectomy only ($n = 285$) and those treated with intra-arterial urokinase ($n = 405$). Logistic regression analyses included age, NIHSS at admission, large vessel occlusion and smoking status as covariates. The results are shown in Tables 2 and 3. Smokers treated with pure mechanical thrombectomy had significantly higher rates of excellent clinical outcome at 3 months as compared to nonsmokers (37.1% vs. 19%, $p = 0.002$), while no differences were detected regarding mortality at 3 months, sICH and recanalization. Logistic regression analysis revealed an independent association for age and NIHSS (OR 0.199, 95% CI 0.942–0.990, $p = 0.006$ and OR 0.856, 95% CI 0.803–0.914, $p < 0.001$, respectively), but not for smoking (OR 1.604, 95% CI 0.724–3.551, $p = 0.244$). Smokers treated with intra-arterial urokinase reached also higher rates of excellent clinical outcome (39.4% vs. 20.9%, $p = 0.001$) and tended to lower mortality risk (15.5% vs. 24.2%, $p = 0.058$). The following variables were strongly associated with excellent clinical outcome: age (OR 0.973, 95% CI 0.954–0.991, $p = 0.004$), NIHSS (OR 0.910, 95% CI 0.872–0.950, $p < 0.001$), smoking (OR 2.412, 95% CI 1.245–4.671, $p = 0.009$).

Table 3. Outcomes after IAT with urokinase in smoking vs. nonsmoking patients.

	All patients (n = 405)	Smokers (n = 73)	Nonsmokers (n = 332)	p
Excellent clinical outcome (mRS 0–1)	96/396 (24.2)	28/71 (39.4)	68/325 (20.9)	0.001
Death	96/396 (24.2)	11/71 (15.5)	85/325 (26.2)	0.058
sICH	20/402 (5)	2/73 (2.7)	18/329 (5.5)	0.332
Successful recanalization	288/402 (71.6)	53/71 (74.6)	235/331 (71)	0.536

Results are expressed in n/N (%)

mRS denotes modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale and sICH, symptomatic intracranial hemorrhage

<https://doi.org/10.1371/journal.pone.0194652.t003>

Discussion

This study suggests that current smoking may be an independent predictor of excellent clinical outcome in ischemic stroke treated with EVT. To date, many studies investigated the relationship between smoking status and outcome after IVT in stroke patients and reported conflicting results.[5, 25–28] However, data on EVT are scarce. Meseguer and colleagues showed that intra-arterial administration of rtPA independently predicts arterial recanalization in smokers, but had no significant impact on clinical endpoints such as favorable outcome, mortality or sICH.[29] However, the cohort size was rather small as compared to our study (227 vs. 935 patients). We are not aware of further studies assessing the relationship between smoking and stroke outcome after EVT.

Considering differences in baseline characteristics is essential for discussion of “smoking paradox” in stroke patients. In line with literature, smokers in our study were significantly younger, more likely to be male and suffered less often from atrial fibrillation and arterial hypertension than nonsmokers.[5, 26, 27, 29] These imbalances could partially explain the better clinical outcomes in favor of smokers, as older age and male gender have been shown to be associated with worse clinical outcomes.[30–33] In line with this, Hussein et al. suggested that smoking paradox may be mainly related to differences in age.[25] In addition, Tong et al. recently reported that noncardioembolic stroke may be independently related to good outcome in smoking patients treated with IVT.[34] Cardioembolism was the underlying stroke reason for almost every second non-smoking patient in our study. Cardioembolic stroke due to atrial fibrillation is considered to be an independent risk factor for large territorial infarcts, hemorrhagic transformation and unfavorable outcome after stroke.[35–37] Furthermore, stroke severity at admission (measured by NIHSS) tended to be lower in smokers which may also have contributed to differences in outcome.[38, 39]

Mechanical thrombectomy was more often used in smokers (36.8% vs. 28.7%), whereas IAT was the preferred treatment in non-smokers (45.4% vs. 35.8%). We assume, that these differences in treatment may primarily be related to higher proportion of large vessel occlusions in smokers.

The relationship between favorable outcome and smoking status after thrombolysis has also been reported in stroke patients treated with IVT.[5] Other studies could not detect an association between outcome and smoking habits though higher rates of recanalization in smokers.[26, 29] The conflicting results may be related to differences in study size as the number of included patients reported in studies range from 94 to 5383.[5, 25] Furthermore, location of vessel occlusion may have played an important role. Smoking patients suffered more frequently from large artery occlusion, which was independently associated with recanalization in this study. The association between higher recanalization rates and proximal vessel occlusion in EVT has already been reported in a large cohort with anterior circulation stroke.[40] In contrary, large vessel occlusion is inversely related to recanalization and outcome in stroke patients treated with IVT.[41–43] Hypercholesterolemia was another independent predictor of recanalization in our study. Vanacker et al. reported an independent association between hypercholesterolemia and spontaneous recanalization in patients with ischemic stroke.[44] Galimanis et al. also observed higher recanalization rates in stroke patients with hypercholesterolemia after EVT.[40] Antioxidant effects of lipids or lower rates of concomitant infections were discussed as potential explanations.[45, 46] Pleiotropic effects of statins in these patients may also be of importance.[47]

An increased efficacy of rtPA in smokers has been reported before with respect to different rates of recanalization depending on thrombus composition.[28, 29] Smoking patients are

assumed to have an increased hematocrit, platelet activation and aggregation, vasoconstriction and circulating fibrinogen.[48–50] Thus, smokers may have more thrombogenic than atherogenic vessel occlusion, whereas nonsmokers may have more likely vessel occlusion due to ruptured or ulcerated plaque with platelet-rich clot.[51] However, we could not prove a strong association between smoking status and recanalization after EVT. Ali et al. reported a lower in-hospital mortality in smoking stroke patients irrespective of thrombolysis and discussed a greater susceptibility of thrombi to therapeutic as well as to spontaneous thrombolysis due to the different thrombus compositions.[51] Our subgroup analyses suggest that smoking may have a greater impact on clinical outcome in patients treated with IA urokinase than in those treated with pure mechanical thrombectomy. This finding could be in line with the abovementioned hypothesis of increased susceptibility of thrombi to fibrinolytic drugs in smokers. Mortality among smokers was also lower in our study, but the association lost significance after adjusting for confounders. Smokers may be supposed to have a better cerebral collateral supply as a further explanation for paradoxical association with clinical outcome, but collateral supply did not differ between groups in our study. Still, smokers may be better preconditioned on ischemia due to increased plasma levels of carbon monoxide and episodic hypoxia.[52] Smoking status had no impact on risk of sICH after treatment in this study, which is in line with literature.[5, 27, 29]

The main strength of this study is the large cohort size, which allows adjustment for potential confounders and decreases the odds for false-positive results. This is to our best knowledge the largest study assessing relationship between EVT and smoking status. Furthermore, data quality was high as both clinical and radiological data were systematically and prospectively collected at baseline and during 3-month follow-up by certified neurologists and neuroradiologists. In addition, we aimed at comprehensive data collection including location of vessel occlusion, recanalization and collateral supply, which were not considered in former studies.

We are aware of several limitations. First, this was an observational study with an inherent risk of treatment bias which may not be completely removed though multivariate model. As consequence, a firm conclusion about causality between smoking and outcome is prohibited. Second, we did not record quantity of smoking exposure, leading to a heterogeneity in our smoking cohort and hindering a differentiation of heavy vs. mild smokers. A dose-dependent relation between smoking and blood viscosity with increase of plasma-fibrinogen level has been reported.[53] Third, there may be some hidden confounders which were not included in our study such as mode and intensity of rehabilitation, socio-economic status and medical complications. Furthermore we did not adjust for other prognostic factors such as time to recanalization or radiological scores of stroke severity. Fourth, current guidelines recommend the use of TICI (Thrombolysis In Cerebral Infarction) study for assessment of arterial recanalization.[54] We used TIMI scale for historical reasons, because recommendation for TICI was published towards the end of our study period. Fifth data were collected over ten years during which a great evolution on stroke treatment was taking place. Especially recanalization techniques and acute stroke care like stroke unit care and early rehabilitation might influence outcome in stroke patients. Nevertheless endovascular stroke therapy has a long tradition in our center and has been systematically performed. The publication of the major randomised controlled trials on EVT did not change our treatment approach. Furthermore the main question was to determine differences between smokers and nonsmokers. Those two groups were treated with same procedures and were affected in a similar way of mentioned changes. Finally, we did not measure changes in smoking habits (e.g. cessation of smoking) after stroke which may also have influenced the 3-month outcome.

Conclusion

In summary, our data indicate that smoking in stroke patients may be independently associated with excellent clinical outcome after EVT. Though strong relationship in multivariable analyses, significant differences in baseline characteristics still needed to be considered together with different pathophysiological mechanisms. A conclusion on causality is not reliable due to the observational study design. Thus, these data must not be misinterpreted as a beneficial effect of smoking. In view of deleterious effects of cigarette smoking on cardiovascular health, cessation of smoking should still be strongly recommended for both primary and secondary stroke prevention

Supporting information

S1 Table. Blockwise-backwards regression analyses for favorable outcome, death after 3 months sICH and recanalization. CI confidence interval, IQR denotes interquartile range, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, OR odds ratio, sICH, symptomatic intracranial hemorrhage. (DOCX)

Acknowledgments

We thank Pietro Ballinari for statistical advice.

Author Contributions

Conceptualization: Hakan Sarikaya.

Data curation: Rascha von Martial, Jan Gralla, Pasquale Mordasini, Marwan El Koussy, Sebastian Bellwald, Rebekka Kurmann, Simon Jung, Urs Fischer, Marcel Arnold, Hakan Sarikaya.

Formal analysis: Rascha von Martial, Bastian Volbers, Hakan Sarikaya.

Project administration: Hakan Sarikaya.

Resources: Jan Gralla, Marwan El Koussy, Simon Jung, Urs Fischer, Marcel Arnold.

Supervision: Hakan Sarikaya.

Writing – original draft: Rascha von Martial, Jan Gralla, Pasquale Mordasini, Hakan Sarikaya.

Writing – review & editing: Rascha von Martial, Jan Gralla, Pasquale Mordasini, Marwan El Koussy, Sebastian Bellwald, Bastian Volbers, Rebekka Kurmann, Simon Jung, Urs Fischer, Marcel Arnold, Hakan Sarikaya.

References

1. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet*. 2010; 376(9735):112–23. Epub 2010/06/22. [https://doi.org/10.1016/S0140-6736\(10\)60834-3](https://doi.org/10.1016/S0140-6736(10)60834-3) PMID: 20561675.
2. Organization WH. WHO global report on trends in prevalence of tobacco smoking 2015. 2015.
3. Sparrow D, Dawber TR. The influence of cigarette smoking on prognosis after a first myocardial infarction. A report from the Framingham study. *J Chronic Dis*. 1978; 31(6–7):425–32. Epub 1978/01/01. PMID: 711834.

4. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmaliotis D, Murphy SA, et al. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. *J Am Coll Cardiol.* 2005; 45(2):321–3. Epub 2005/01/18. <https://doi.org/10.1016/j.jacc.2004.10.018> PMID: 15653037.
5. Kvistad CE, Oeygarden H, Logallo N, Thomassen L, Waje-Andreassen U, Naess H. Is smoking associated with favourable outcome in tPA-treated stroke patients? *Acta neurologica Scandinavica.* 2014; 130(5):299–304. Epub 2014/02/18. <https://doi.org/10.1111/ane.12225> PMID: 24527872.
6. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* 2015; 46(10):3020–35. Epub 2015/07/01. <https://doi.org/10.1161/STR.0000000000000074> PMID: 26123479.
7. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med.* 2015; 372(24):2285–95. Epub 2015/04/18. <https://doi.org/10.1056/NEJMoa1415061> PMID: 25882376.
8. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* 2015; 372(1):11–20. Epub 2014/12/18. <https://doi.org/10.1056/NEJMoa1411587> PMID: 25517348.
9. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* 2015; 372(11):1019–30. Epub 2015/02/12. <https://doi.org/10.1056/NEJMoa1414905> PMID: 25671798.
10. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke.* 1993; 24(1):35–41. Epub 1993/01/01. PMID: 7678184.
11. Nedeltchev K, Fischer U, Arnold M, Ballinari P, Haefeli T, Kappeler L, et al. Long-term effect of intra-arterial thrombolysis in stroke. *Stroke.* 2006; 37(12):3002–7. Epub 2006/10/28. <https://doi.org/10.1161/01.STR.0000249417.24085.80> PMID: 17068302.
12. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke.* 1988; 19(5):604–7. Epub 1988/05/01. PMID: 3363593.
13. Brott T, Adams HP Jr., Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. *Stroke.* 1989; 20(7):864–70. Epub 1989/07/01. PMID: 2749846.
14. Fischer U, Mono ML, Schroth G, Jung S, Mordasini P, El-Koussy M, et al. Endovascular therapy in 201 patients with acute symptomatic occlusion of the internal carotid artery. *Eur J Neurol.* 2013; 20(7):1017–24, e87. Epub 2013/02/13. <https://doi.org/10.1111/ene.12094> PMID: 23398194.
15. Heldner MR, Jung S, Zubler C, Mordasini P, Weck A, Mono ML, et al. Outcome of patients with occlusions of the internal carotid artery or the main stem of the middle cerebral artery with NIHSS score of less than 5: comparison between thrombolysed and non-thrombolysed patients. *J Neurol Neurosurg Psychiatry.* 2015; 86(7):755–60. Epub 2014/10/01. <https://doi.org/10.1136/jnnp-2014-308401> PMID: 25266203.
16. Luedi R, Hsieh K, Slezak A, El-Koussy M, Fischer U, Heldner MR, et al. Age dependency of safety and outcome of endovascular therapy for acute stroke. *J Neurol.* 2014; 261(8):1622–7. Epub 2014/06/12. <https://doi.org/10.1007/s00415-014-7401-0> PMID: 24916832.
17. Arnold M, Nedeltchev K, Schroth G, Baumgartner RW, Remonda L, Loher TJ, et al. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. *J Neurol Neurosurg Psychiatry.* 2004; 75(6):857–62. Epub 2004/05/18. <https://doi.org/10.1136/jnnp.2003.020479> PMID: 15146000
18. Arnold M, Schroth G, Nedeltchev K, Loher T, Remonda L, Stepper F, et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. *Stroke.* 2002; 33(7):1828–33. Epub 2002/07/10. PMID: 12105361.
19. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet.* 1998; 352(9136):1245–51. Epub 1998/10/27. PMID: 9788453.
20. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. *N Engl J Med.* 1985; 312(14):932–6. Epub 1985/04/04. <https://doi.org/10.1056/NEJM198504043121437> PMID: 4038784.
21. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and

- intravenous streptokinase. Clinical findings through hospital discharge. *Circulation*. 1987; 76(1):142–54. Epub 1987/07/01. PMID: [3109764](https://pubmed.ncbi.nlm.nih.gov/3109764/).
22. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. *Stroke*. 2005; 36(7):1432–8. Epub 2005/06/18. <https://doi.org/10.1161/01.STR.0000171066.25248.1d> PMID: [15961709](https://pubmed.ncbi.nlm.nih.gov/15961709/).
 23. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. *Lancet*. 2012; 380(9849):1241–9. Epub 2012/08/31. [https://doi.org/10.1016/S0140-6736\(12\)61384-1](https://doi.org/10.1016/S0140-6736(12)61384-1) PMID: [22932715](https://pubmed.ncbi.nlm.nih.gov/22932715/).
 24. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira R, et al. SOLITAIRE with the intention for thrombectomy (SWIFT) trial: design of a randomized, controlled, multicenter study comparing the SOLITAIRE Flow Restoration device and the MERCI Retriever in acute ischaemic stroke. *Int J Stroke*. 2014; 9(5):658–68. Epub 2012/11/08. <https://doi.org/10.1111/j.1747-4949.2012.00856.x> PMID: [23130938](https://pubmed.ncbi.nlm.nih.gov/23130938/).
 25. Hussein HM, Niemann N, Parker ED, Qureshi AI. Searching for the Smoker's Paradox in Acute Stroke Patients Treated With Intravenous Thrombolysis. *Nicotine Tob Res*. 2017. Epub 2017/03/25. <https://doi.org/10.1093/ntr/ntx020> PMID: [28339617](https://pubmed.ncbi.nlm.nih.gov/28339617/).
 26. Kufner A, Nolte CH, Galinovic I, Brunecker P, Kufner GM, Endres M, et al. Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke. *Stroke; a journal of cerebral circulation*. 2013; 44(2):407–13. Epub 2013/01/05. <https://doi.org/10.1161/STROKEAHA.112.662148> PMID: [23287785](https://pubmed.ncbi.nlm.nih.gov/23287785/).
 27. Aries MJ, Uyttenboogaart M, Koch MW, Langedijk M, Vroomen PC, Luijckx GJ, et al. Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke? *Eur J Neurol*. 2009; 16(7):819–22. Epub 2009/05/29. <https://doi.org/10.1111/j.1468-1331.2009.02596.x> PMID: [19473358](https://pubmed.ncbi.nlm.nih.gov/19473358/).
 28. Ovbiagele B, Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke. *Neurology*. 2005; 65(2):293–5. Epub 2005/07/27. <https://doi.org/10.1212/01.wnl.0000168163.72351.f3> PMID: [16043802](https://pubmed.ncbi.nlm.nih.gov/16043802/).
 29. Meseguer E, Labreuche J, Gonzalez-Valcarcel J, Sirimarco G, Guidoux C, Cabrejo L, et al. The smoking paradox: impact of smoking on recanalization in the setting of intra-arterial thrombolysis. *Cerebrovasc Dis Extra*. 2014; 4(2):84–91. Epub 2014/06/14. <https://doi.org/10.1159/000357218> PMID: [24926305](https://pubmed.ncbi.nlm.nih.gov/24926305/)
 30. Palnum KD, Petersen P, Sorensen HT, Ingeman A, Mainz J, Bartels P, et al. Older patients with acute stroke in Denmark: quality of care and short-term mortality. A nationwide follow-up study. *Age Ageing*. 2008; 37(1):90–5. Epub 2007/10/30. <https://doi.org/10.1093/ageing/afm134> PMID: [17965039](https://pubmed.ncbi.nlm.nih.gov/17965039/).
 31. Smith EE, Shobha N, Dai D, Olson DM, Reeves MJ, Saver JL, et al. Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines–Stroke Program. *Circulation*. 2010; 122(15):1496–504. Epub 2010/09/30. <https://doi.org/10.1161/CIRCULATIONAHA.109.932822> PMID: [20876438](https://pubmed.ncbi.nlm.nih.gov/20876438/).
 32. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CD, et al. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. *Stroke*. 2003; 34(5):1114–9. Epub 2003/04/12. <https://doi.org/10.1161/01.STR.0000068410.07397.D7> PMID: [12690218](https://pubmed.ncbi.nlm.nih.gov/12690218/).
 33. De Silva DA, Ebinger M, Davis SM. Gender issues in acute stroke thrombolysis. *J Clin Neurosci*. 2009; 16(4):501–4. Epub 2009/02/10. <https://doi.org/10.1016/j.jocn.2008.07.068> PMID: [19201193](https://pubmed.ncbi.nlm.nih.gov/19201193/).
 34. Tong X, Wang C, Liao X, Pan Y, Yan H, Cao Y, et al. Smoking-Thrombolysis Relationship Depends on Ischemic Stroke Subtype. *Stroke*. 2016; 47(7):1811–6. Epub 2016/05/26. <https://doi.org/10.1161/STROKEAHA.116.013124> PMID: [27222526](https://pubmed.ncbi.nlm.nih.gov/27222526/).
 35. Urbach H, Hartmann A, Pohl C, Omran H, Wilhelm K, Flacke S, et al. Local intra-arterial thrombolysis in the carotid territory: does recanalization depend on the thromboembolus type? *Neuroradiology*. 2002; 44(8):695–9. Epub 2002/08/20. <https://doi.org/10.1007/s00234-002-0762-6> PMID: [12185548](https://pubmed.ncbi.nlm.nih.gov/12185548/).
 36. Arboix A, Alio J. Acute cardioembolic stroke: an update. *Expert Rev Cardiovasc Ther*. 2011; 9(3):367–79. Epub 2011/03/29. <https://doi.org/10.1586/erc.10.192> PMID: [21438816](https://pubmed.ncbi.nlm.nih.gov/21438816/).
 37. Wang XG, Zhang LQ, Liao XL, Pan YS, Shi YZ, Wang CJ, et al. Unfavorable Outcome of Thrombolysis in Chinese Patients with Cardioembolic Stroke: a Prospective Cohort Study. *CNS Neurosci Ther*. 2015; 21(8):657–61. Epub 2015/06/23. <https://doi.org/10.1111/cns.12421> PMID: [26096605](https://pubmed.ncbi.nlm.nih.gov/26096605/).
 38. Adams HP Jr., Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). *Neurology*. 1999; 53(1):126–31. Epub 1999/07/17. PMID: [10408548](https://pubmed.ncbi.nlm.nih.gov/10408548/).
 39. Yaghi S, Willey JZ, Andrews H, Boehme AK, Marshall RS, Boden-Albala B. The Itemized NIHSS Scores Are Associated With Discharge Disposition in Patients With Minor Stroke. *Neurohospitalist*. 2016; 6(3):102–6. Epub 2016/07/02. <https://doi.org/10.1177/1941874416641466> PMID: [27366292](https://pubmed.ncbi.nlm.nih.gov/27366292/)

40. Galimanis A, Jung S, Mono ML, Fischer U, Findling O, Weck A, et al. Endovascular therapy of 623 patients with anterior circulation stroke. *Stroke*. 2012; 43(4):1052–7. Epub 2012/03/01. <https://doi.org/10.1161/STROKEAHA.111.639112> PMID: 22363057.
41. Medlin F, Amiguet M, Vanacker P, Michel P. Influence of arterial occlusion on outcome after intravenous thrombolysis for acute ischemic stroke. *Stroke*. 2015; 46(1):126–31. Epub 2014/11/27. <https://doi.org/10.1161/STROKEAHA.114.006408> PMID: 25424477.
42. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. *Stroke*. 2007; 38(3):948–54. Epub 2007/02/10. <https://doi.org/10.1161/01.STR.0000257304.21967.ba> PMID: 17290031.
43. Bhatia R, Shobha N, Menon BK, Bal SP, Kochar P, Palumbo V, et al. Combined full-dose IV and endovascular thrombolysis in acute ischaemic stroke. *Int J Stroke*. 2014; 9(8):974–9. Epub 2012/09/28. <https://doi.org/10.1111/j.1747-4949.2012.00890.x> PMID: 23013039.
44. Vanacker P, Lambrou D, Eskandari A, Ntaios G, Cras P, Maeder P, et al. Improving the Prediction of Spontaneous and Post-thrombolytic Recanalization in Ischemic Stroke Patients. *J Stroke Cerebrovasc Dis*. 2015; 24(8):1781–6. Epub 2015/05/28. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.04.002> PMID: 26015095.
45. Olsen TS, Christensen RH, Kammergaard LP, Andersen KK. Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. *Stroke*. 2007; 38(10):2646–51. Epub 2007/09/01. <https://doi.org/10.1161/STROKEAHA.107.490292> PMID: 17761907.
46. Arboix A, Garcia-Eroles L, Oliveres M, Targa C, Balcells M, Massons J. Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? *BMC Neurol*. 2010; 10:47. Epub 2010/06/23. <https://doi.org/10.1186/1471-2377-10-47> PMID: 20565890
47. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. *Circ Res*. 2017; 120(1):229–43. Epub 2017/01/07. <https://doi.org/10.1161/CIRCRESAHA.116.308537> PMID: 28057795.
48. Undas A, Topor-Madry R, Tracz W, Pasowicz M. Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. *Thromb Haemost*. 2009; 102(6):1289–91. Epub 2009/12/08. <https://doi.org/10.1160/TH09-03-0187> PMID: 19967167.
49. Purcell IF, Newall N, Farrer M. Lower cardiac mortality in smokers following thrombolysis for acute myocardial infarction may be related to more effective fibrinolysis. *Qjm*. 1999; 92(6):327–33. Epub 2000/01/05. PMID: 10616708.
50. McGill HC Jr. The cardiovascular pathology of smoking. *Am Heart J*. 1988; 115(1 Pt 2):250–7. Epub 1988/01/01. PMID: 3276113.
51. Ali SF, Smith EE, Bhatt DL, Fonarow GC, Schwamm LH. Paradoxical association of smoking with in-hospital mortality among patients admitted with acute ischemic stroke. *J Am Heart Assoc*. 2013; 2(3):e000171. Epub 2013/06/21. <https://doi.org/10.1161/JAHA.113.000171> PMID: 23782919.
52. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. *Chest*. 2000; 117(3):758–63. Epub 2000/03/14. PMID: 10713003.
53. Ernst E, Matrai A, Schmolzl C, Magyarosy I. Dose-effect relationship between smoking and blood rheology. *Br J Haematol*. 1987; 65(4):485–7. Epub 1987/04/01. PMID: 3580306.
54. Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke*. 2013; 44(9):2650–63. Epub 2013/08/08. <https://doi.org/10.1161/STROKEAHA.113.001972> PMID: 23920012.